InfYnity-Biomarkers, Ecully, France ; Laboratory of Bacteriology-Virology, GIMAP EA3064, Faculty of Medicine Jacques Lisfranc, Saint-Etienne, France.
PLoS One. 2013 Sep 17;8(9):e74493. doi: 10.1371/journal.pone.0074493. eCollection 2013.
Cross-reactive antibodies are characterized by their recognition of antigens that are different from the trigger immunogen. This happens when the similarity between two different antigenic determinants becomes adequate enough to enable a specific binding with such cross-reactive antibodies. In the present manuscript, we report the presence, at an "abnormal" high frequency, of antibodies in blood samples from French human subjects cross-reacting with a synthetic-peptide antigen derived from a Trypanosoma cruzi (T. cruzi) protein sequence. As the vector of T. cruzi is virtually confined to South America, the parasite is unlikely to be the trigger immunogen of the cross-reactive antibodies detected in France. At present, the cross-reactive antibodies are measured by using an in-house ELISA method that employs the T. cruzi -peptide antigen. However, to underline their cross-reactive characteristics, we called these antibodies "Trypanosoma cruzi Cross Reactive Antibodies" or TcCRA. To validate their cross-reactive nature, these antibodies were affinity-purified from plasma of healthy blood donor and were then shown to specifically react with the T. cruzi parasite by immunofluorescence. Seroprevalence of TcCRA was estimated at 45% in serum samples of French blood donors while the same peptide-antigen reacts with about 96% of T. cruzi -infected Brazilian individuals. In addition, we compared the serology of TcCRA to other serologies such as HSV 1/2, EBV, HHV-6, CMV, VZV, adenovirus, parvovirus B19, mumps virus, rubella virus, respiratory syncytial virus, measles and enterovirus. No association was identified to any of the tested viruses. Furthermore, we tested sera from different age groups for TcCRA and found a progressive acquisition starting from early childhood. Our findings show a large seroprevalence of cross-reactive antibodies to a well-defined T. cruzi antigen and suggest they are induced by a widely spread immunogen, acquired from childhood. The etiology of TcCRA and their clinical relevance still need to be investigated.
交叉反应性抗体的特点是识别与触发免疫原不同的抗原。当两种不同抗原决定簇之间的相似性足够高时,就会发生这种情况,从而使这些交叉反应性抗体能够与抗原发生特异性结合。在本手稿中,我们报告了在法国人类血液样本中存在的、频率异常高的抗体,这些抗体与一种源自克氏锥虫(T. cruzi)蛋白序列的合成肽抗原发生交叉反应。由于 T. cruzi 的载体实际上仅限于南美洲,因此这种寄生虫不太可能是在法国检测到的交叉反应性抗体的触发免疫原。目前,这些交叉反应性抗体是通过使用一种内部 ELISA 方法来测量的,该方法使用 T. cruzi 肽抗原。然而,为了强调它们的交叉反应特性,我们将这些抗体称为“克氏锥虫交叉反应抗体”或 TcCRA。为了验证它们的交叉反应性质,我们从健康献血者的血浆中亲和纯化了这些抗体,然后通过免疫荧光显示它们特异性地与 T. cruzi 寄生虫反应。在法国献血者的血清样本中,TcCRA 的血清流行率估计为 45%,而相同的肽抗原与约 96%的 T. cruzi 感染巴西个体发生反应。此外,我们将 TcCRA 的血清学与其他血清学(如 HSV 1/2、EBV、HHV-6、CMV、VZV、腺病毒、细小病毒 B19、腮腺炎病毒、风疹病毒、呼吸道合胞病毒、麻疹和肠道病毒)进行了比较。未发现与任何一种测试病毒有关。此外,我们测试了不同年龄组的 TcCRA 血清,发现从幼儿期开始就逐渐获得了这些抗体。我们的研究结果表明,针对一种明确的 T. cruzi 抗原存在广泛的交叉反应性抗体血清流行率,并表明这些抗体是由广泛传播的免疫原诱导产生的,这些免疫原在儿童时期就已经获得。TcCRA 的病因及其临床意义仍需要进一步研究。